Among small-capitalization companies in the Covid-19 race, Tonix Pharmaceuticals (NASDAQ:TNXP) may be worth consideration with what I would term “dumb money.” Currently, TNXP stock is trading hands for less than a buck, which immediately tells you something about this opportunity’s risk profile.
FingerMotion could be on an exponential growth trajectory and the stock price along with it. Their large inflow of capital should be responsible for another strong performance in the current quarter. AliBaba’s (NASDAQ: BABA) singles day (November 11th) is in the current quarter.
After the initial deadly volley from the novel coronavirus, the broader healthcare industry’s attention shifted from developing treatments to researching and developing vaccines. Not...
The recent pandemic brought with it both a collapse in energy prices and stock markets, followed by a massive run-up in stocks to which big oil majors like Lukoil (OTCMKTS: LUKOY), Gazprom (OTCMKTS: OGZPY), Total S.A. (NYSE: TOT), Exxon (NYSE: XOM), BP plc (NYSE: BP), Chevron (NYSE: CVX), and Phillips 66 (NYSE: PSX) have only marginally benefited from. With the energy shakeout continuing, unexpected new winners have emerged servicing regional niche markets who are poised to make serious cash flow.
Galectin Therapeutics Inc. (NASDAQ: GALT) shot up close to 32.4% on Monday on record breaking volume of 4.9 million shares in anticipation of a long awaited investor conference call at 4PM ET on September 29th. In after hours trading the stock continues to climb to $4.20. GALT has one of the worst track records when it comes to shareholder communications with only 9 press releases this year, so it's easy to see why shareholders might be excited and speculating on news during the conference. GALT’s long term holders have pointed to outgoing CEO Harold Shlevin for the lack of communication while he focused on finishing the NASH phase 3 clinical trial design which took close to 2 years to complete.
While the list of those garnering the most attention read like the usual suspects, there’s probably one biotech firm you haven’t heard of, VBI Vaccines (NASDAQ:VBIV). While VBIV stock soared to multi-year highs around mid-July, shares have found themselves plummeting back to earth. As several now well-known vaccine companies have entered into late-stage clinical trials for their Covid-19 candidates, the other, smaller names have lost their luster.
QEBR (OTC Pink: QEBR) has 300 machines configured to engage the Filecoin (FIL) network. Based on internal estimates, each machine has the possibility to mine 358 Filecoin reward tokens per month. At an expected price of $22.52 per coin, QEBR, assuming no changes to the hardware count, could generate nearly $2.42 million in revenue per month.
US media hasn’t picked up on the linkage to DELL and INTC. The potential of a 20 second COVID-19 test is “priceless”. The existence of this test allows governments to loosen social distancing restrictions as they get used at schools, universities, airports, hospitals, sporting events...the list is endless!
This is a play on the treatment of Covid-19 rather than a preventative vaccine Before the pandemic, one of the flagship drugs under the Can-Fite pipeline was Piclidenoson. An orally administered drug, Piclidenoson is essentially a small-molecule inhibitor that targets enzymes that cause inflammation.
It’s a big world out there. While investors should maintain their core holdings in strong, U.S.-based companies with reasonable growth and earnings trajectories, the...